Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: Myth or reality

International Journal of Angiology

Volumn 23, Issue 1, 2014, Pages 11-16

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

advanced glycation end products; biomarker; coronary artery disease; diabetes; endogenous secretory receptor for AGEs; renal dysfunction; soluble receptor for AGEs; unified biomarker for AGE RAGE associated diseases

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; COLLAGENASE 3; ENDOGENOUS SECRETORY ADVANCED GLYCATION END PRODUCT RECEPTOR; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; STROMELYSIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROTECTION; CELLULAR SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RECEPTOR BINDING; REVIEW; URINARY EXCRETION;

EID: 84896694901     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0033-1363423     Document Type: Review

References (69)

1. Takeuchi M., Yanase Y., Matsuura N., et al. Immunological detection of a novel advanced glycation end-product. Mol Med: 2001; 7 11 783 791
2. Thorpe S. R., Baynes J. W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids: 2003; 25 3-4 275 281
3. Bierhaus A., Hofmann M. A., Ziegler R., Nawroth P. P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res: 1998; 37 3 586 600
4. Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol: 2006; 15 57 68
5. Neeper M., Schmidt A. M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem: 1992; 267 21 14998 15004
6. Wendt T., Tanji N., Guo J., et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol: 2003; 14 5 1383 1395
7. Schmidt A. M., Yan S. D., Wautier J. L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res: 1999; 84 5 489 497
8. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta: 2000; 1498 2-3 99 111
9. Tam X. HL, Shiu S. WM, Leng L., Bucala R., Betteridge D. J., Tan K. CB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond): 2011; 120 2 81 89
10. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol: 2005; 25 12 2587 2593
11. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem: 2006; 13 17 1971 1978
12. Colhoun H. M., Betteridge D. J., Durrington P., et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes: 2011; 60 9 2379 2385
13. Fujisawa K., Katakami N., Kaneto H., et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis: 2013; 227 2 425 428
14. Tan K. CB, Shiu S. WM, Chow W. S., Leng L., Bucala R., Betteridge D. J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia: 2006; 49 11 2756 2762
15. Challier M., Jacqueminet S., Benabdesselam O., Grimaldi A., Beaudeux J. L. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem: 2005; 51 9 1749 1750
16. Nin J. W., Jorsal A., Ferreira I., et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes: 2010; 59 8 2027 2032
17. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care: 2005; 28 11 2716 2721
18. Kalousová M., Hodková M., Kazderová M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis: 2006; 47 3 406 411
19. Basta G., Leonardis D., Mallamaci F., et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int: 2010; 77 3 225 231
20. Nin J. WM, Ferreira I., Schalkwijk C. G., et al. EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia: 2009; 52 4 705 714
21. Hammady M. MR, Khashali S. EL, Halim H. A., Rashed L., Hussein M. Soluble receptor for advanced glycation end products (sRAGE) in non-diabetic hemodialysis patients and chronic kidney disease. Med J Cairo Univ: 2012; 80 69 75
22. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol: 2005; 25 5 1032 1037
23. Lindsey J. B., de Lemos J. A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care: 2009; 32 7 1218 1220
24. Hudson B. I., Moon Y. P., Kalea A. Z., et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis: 2011; 216 1 192 198
25. Selvin E. M., Halushka M. K., Rawlings A. M., et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes: 2013; 62 6 2116 2121
26. McNair E. D., Wells C. R., Qureshi A. M., et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol: 2009; 18 4 187 192
27. McNair E. D., Wells C. R., Mabood Qureshi A., et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol: 2010; 33 11 678 685
28. Santilli F., Bucciarelli L., Noto D., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med: 2007; 43 9 1255 1262
29. Geroldi D., Falcone C., Emanuele E., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens: 2005; 23 9 1725 1729
30. Emanuele E., D'Angelo A., Tomaino C., et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol: 2005; 62 11 1734 1736
31. Miniati M., Monti S., Basta G., Cocci F., Fornai E., Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res: 2011; 12 37 45
32. Smith D. J., Yerkovich S. T., Towers M. A., Carroll M. L., Thomas R., Upham J. W. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J: 2011; 37 3 516 522
33. Wang L. J., Lu L., Zhang F. R., Chen Q. J., De Caterina R., Shen W. F. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail: 2011; 13 4 440 449
34. Basta G., Berti S., Cocci F., et al. Plasma N-epsilon-(carboxymethyl) lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis: 2008; 19 5 299 305
35. Taki K., Takayama F., Tsuruta Y., Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int: 2006; 70 1 218 224
36. Tan K. CB, Chow W. S., Tam S., Bucala R., Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care: 2004; 27 1 223 228
37. Berg T. J., Dahl-Jorgensen K., Torjesen P. A., Hanssen K. F. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care: 1997; 20 6 1006 1008
38. Berg T. J., Clausen J. T., Torjesen P. A., Dahl-Jorgensen K., Bangstad H. J., Hanssen K. F. The advanced glycation end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care: 1998; 21 11 1997 2002
39. Sharp P. S., Rainbow S., Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med: 2003; 20 7 575 579
40. Kilhovd B. K., Berg T. J., Birkeland K. I., Thorsby P., Hanssen K. F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care: 1999; 22 9 1543 1548
41. Kanauchi M., Tsujimoto N., Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care: 2001; 24 9 1620 1623
42. Selvaraj N., Bobby Z., Das A. K., Ramesh R., Koner B. C. An evaluation of level of oxidative stress and protein glycation in nondiabetic undialyzed chronic renal failure patients. Clin Chim Acta: 2002; 324 1-2 45 50
43. Shimoike T., Inoguchi T., Umeda F., Nawata H., Kawano K., Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism: 2000; 49 8 1030 1035
44. Raj D. S., Choudhury D., Welbourne T. C., Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis: 2000; 35 3 365 380
45. Papanastasiou P., Grass L., Rodela H., Patrikarea A., Oreopoulos D., Diamandis E. P. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int: 1994; 46 1 216 222
46. Makita Z., Radoff S., Rayfield E. J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med: 1991; 325 12 836 842
47. Miyata T., van Ypersele de Strihou C., Kurokawa K., Baynes J. W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of carbonyl stress in long-term uremic complications. Kidney Int: 1999; 55 2 389 399
48. Schmidt A. M., Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep: 2000; 2 5 430 436
49. Beirhaus A., Schiekofer S., Schwaninger M., et al. P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes: 2001; 50(2) 2792 2808
50. Zhang W. R., Hou F. F., Liu S. X., et al. Advanced glycation end products accelerate atherosclerosis via enhancement of oxidative stress [in Chinese]. Zhonghua Yi Xue Za Zhi: 2004; 84 13 1066 1072
51. Ritthaler U., Deng Y., Zhang Y., et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol: 1995; 146 3 688 694
52. Soulis T., Thallas V., Youssef S., et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia: 1997; 40 6 619 628
53. Miura J., Yamamoto Y., Osawa M., et al. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol: 2007; 27 1 253 254
54. Stitt A. W., He C., Friedman S., et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med: 1997; 3 9 617 627
55. Yamagishi S., Adachi H., Nakamura K., et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism: 2006; 55 9 1227 1231
56. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J: 2003; 370 Pt 3 1097 1109
57. Zhang F., Kent K. C., Yamanouchi D., et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg: 2009; 250 3 416 423
58. Zhang F., Banker G., Liu X., et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res: 2011; 171 2 871 876
59. Rasheed Z., Anbazhagan A. N., Akhtar N., Ramamurthy S., Voss F. R., Haqqi T. M. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end products- induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther: 2009; 11 R71
60. Nah S. S., Choi I. Y., Yoo B., Kim Y. G., Moon H. B., Lee C. K. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-α in human osteoarthritic chondrocytes. FEBS Lett: 2007; 581 9 1928 1932
61. Dai R., Wang L., Jim H., Sun Z. Effects of advanced glycation end products on expression of EMMPRIN and MMP-2 in moue osteoblast. African J Pharmac Pharmacol.: 2010; 4 453 464
62. Uemura S., Matsushita H., Li W., et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res: 2001; 88 12 1291 1298
63. Hoffmann S., Friedrichs U., Eichler W., Rosenthal A., Wiedemann P. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol: 2002; 240 12 996 1002
64. Zhu P., Ren M., Yang C., Hu Y. X., Ran J. M., Yan L. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol: 2012; 21 2 123 129
65. Zhang F., Banker G., Liu X., et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res: 2011; 171 2 871 876
66. Song W., Ergul A. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol: 2006; 5 3
67. Rajagopalan S., Meng X. P., Ramasamy S., Harrison D. G., Galis Z. S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest: 1996; 98 11 2572 2579
68. Siwik D. A., Pagano P. J., Colucci W. S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol: 2001; 280 1 C53 C60
69. Koyama H., Yamamoto H., Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights: 2007; 2 331 339